Ulcerative Colitis Therapeutics - Global Market Trajectory & Analytics

DESCRIPTION
TABLE OF CONTENTS

1 of 2

LOGIN TO ACCESS EXECUTIVE SUMMARY
PRINTER FRIENDLY

Global Ulcerative Colitis Therapeutics Market to Reach $7.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Ulcerative Colitis Therapeutics estimated at US$5.6 Billion in the year 2020, is projected to reach a revised size of US$7.9 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Ulcerative Proctitis, one of the segments analyzed in the report, is projected to record a 4.7% CAGR and reach US$2.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Proctosigmoiditis segment is readjusted to a revised 5.4% CAGR for the next 7-year period.

Global Market for Ulcerative Colitis Therapeutics

The U.S. Market is Estimated at $1.7 Billion, While China is Forecast to Grow at 4.8% CAGR

The Ulcerative Colitis Therapeutics market in the U.S. is estimated at US$1.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Left-sided Colitis Segment to Record 5.7% CAGR

In the global Left-sided Colitis segment, USA, Canada, Japan, China and Europe will drive the 5.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.4 Billion in the year 2020 will reach a projected size of US$2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$912.9 Million by the year 2027.

Select Competitors (Total 42 Featured):

Abbott Laboratories, Inc.
AbbVie, Inc.
Amgen, Inc.
Arena Pharmaceuticals, Inc.
Astellas Pharma, Inc.
AstraZeneca PLC
Avaxia Biologics, Inc.
BioLineRx Ltd.
Celgene Corporation
Cosmo Pharmaceuticals NV
EA Pharma Co., Ltd.
Eisai Co., Ltd.
Ferring Pharmaceuticals
Galapagos NV
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Hutchison MediPharma Limited
Immune Pharmaceuticals, Inc.
InDex Pharmaceuticals Holding AB
Janssen Biotech, Inc.
Kaken Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.
Lipid Therapeutics GmbH
Meda AB
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Mochida Pharmaceutical Co., Ltd.
Morphotek, Inc.
Nestle SA
Pfizer, Inc.
Procter & Gamble Company, The
Qu Biologics Inc.
Salix Pharmaceuticals, Inc.
Shield Therapeutics PLC
Shire Pharmaceuticals, Inc.
Sterna Biologicals GmbH & Co. KG
Takeda Pharmaceuticals Company Ltd.
Tillotts Pharma AG
TopiVert Ltd.
UCB SA
Zeria Pharmaceutical Co., Ltd.

Note: Product cover images may vary from those shown

2 of 2

LOGIN TO ACCESS EXECUTIVE SUMMARY
PRINTER FRIENDLY

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Current & Future Analysis for Ulcerative Colitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Ulcerative Colitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Ulcerative Colitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
Table 4: World Current & Future Analysis for Ulcerative Proctitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for Ulcerative Proctitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 6: World 15-Year Perspective for Ulcerative Proctitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Proctosigmoiditis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 8: World Historic Review for Proctosigmoiditis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Proctosigmoiditis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for Left-sided Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 11: World Historic Review for Left-sided Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Left-sided Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 13: World Current & Future Analysis for Pancolitis or Universal Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 14: World Historic Review for Pancolitis or Universal Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Pancolitis or Universal Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for Fulminant Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Fulminant Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Fulminant Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 19: World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 20: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 22: World Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 23: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 24: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 25: USA Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 26: USA Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 27: USA 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 28: USA Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 29: USA Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 30: USA 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027
CANADA
Table 31: Canada Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 32: Canada Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 33: Canada 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 34: Canada Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 35: Canada Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 36: Canada 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027
JAPAN
Table 37: Japan Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 38: Japan Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 39: Japan 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 40: Japan Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 41: Japan Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 42: Japan 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027
CHINA
Table 43: China Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 44: China Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 45: China 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 46: China Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 47: China Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 48: China 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027
EUROPE
Table 49: Europe Current & Future Analysis for Ulcerative Colitis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 50: Europe Historic Review for Ulcerative Colitis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 51: Europe 15-Year Perspective for Ulcerative Colitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Table 52: Europe Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 53: Europe Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 54: Europe 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 55: Europe Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 56: Europe Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 57: Europe 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027
FRANCE
Table 58: France Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 59: France Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 60: France 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 61: France Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 62: France Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 63: France 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027
GERMANY
Table 64: Germany Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 65: Germany Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 66: Germany 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 67: Germany Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 68: Germany Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 69: Germany 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027
ITALY
Table 70: Italy Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 71: Italy Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 72: Italy 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 73: Italy Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 74: Italy Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 75: Italy 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 76: UK Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 77: UK Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 78: UK 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 79: UK Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 80: UK Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 81: UK 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027
REST OF EUROPE
Table 82: Rest of Europe Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 83: Rest of Europe Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 84: Rest of Europe 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 85: Rest of Europe Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 86: Rest of Europe Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 87: Rest of Europe 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Table 88: Asia-Pacific Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 89: Asia-Pacific Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 90: Asia-Pacific 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 91: Asia-Pacific Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 92: Asia-Pacific Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 93: Asia-Pacific 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027
REST OF WORLD
Table 94: Rest of World Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 95: Rest of World Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 96: Rest of World 15-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis and Fulminant Colitis for the Years 2012, 2020 & 2027
Table 97: Rest of World Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 98: Rest of World Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 99: Rest of World 15-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2012, 2020 & 2027